Browsing Institutt for helse og samfunn by Author "Frigstad, Svein Oskar"

Now showing items 1-4 of 4

  • Colorectal cancer screening with repeated fecal immunochemical test versus sigmoidoscopy: baseline results from a randomized trial 
    Randel, Kristin Ranheim; Schult, Anna Lisa; Botteri, Edoardo; Hoff, Geir; Bretthauer, Michael; Ursin, Giske; Natvig, Erik; Berstad, Paula; Jørgensen, Anita; Sandvei, Per Kristian; Olsen, Marie Kristin Ek; Frigstad, Svein Oskar; Darre-Næss, Ole; Norvard, Espen R.; Bolstad, Nils; Kørner, Hartwig; Wibe, Arne; Wensaas, Knut-Arne; de Lange, Thomas; Holme, Øyvind (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Background and aims: The comparative effectiveness of sigmoidoscopy and fecal immunochemical testing (FIT) for colorectal cancer (CRC) screening is unknown. Methods: Individuals aged 50-74 years living in South-East Norway ...
  • Fatigue in patients with newly diagnosed inflammatory bowel disease: Results from a prospective inception cohort, the IBSEN III study 
    Holten, Kristina Ingeborg; Bernklev, Tomm; Opheim, Randi; Johansen, Ingunn; Olsen, Bjørn Christian Elias Grova; Lund, Charlotte; Strande, Vibeke; Medhus, Asle Wilhelm; Perminow, Gøri Margrete; Bengtson, May-Bente; Boyar Cetinkaya, Raziye; Vatn, Simen Svendsen; Frigstad, Svein Oskar; Aabrekk, Tone Bergene; Detlie, Trond Espen; Hovde, Øistein; Kristensen, Vendel Ailin; Småstuen, Milada Cvancarova; Henriksen, Magne; Huppertz-Hauss, Gert; Høivik, Marte Lie; Jelsness-Jørgensen, Lars-Petter (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
    Background and aims: Although fatigue is common in inflammatory bowel disease (IBD), its pathogenesis remains unclear. This study aimed to determine the prevalence of fatigue and its associated factors in a cohort of ...
  • Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway 
    Kristensen, Vendel Ailin; Opheim, Randi; Perminow, Gøri Margrete; Huppertz-Hauss, Gert; Detlie, Trond Espen; Lund, Charlotte; Andersen, Svend; Olsen, Bjørn Christian Elias Grova; Johansen, Ingunn; Medhus, Asle Wilhelm; Vatn, Simen Svendsen; Brackmann, Stephan; Olbjørn, Christine; Rove, Jon Berggren; Henriksen, Magne; Løvlund, Emma Elisabeth; Bengtson, May-Bente; Aabrekk, Tone Bergene; Tønnessen, Tor; Vikskjold, Florin Berge; Yassin, Hussain Ali Ghalib; Frigstad, Svein Oskar; Hasund, Audun; Høie, Ole Ingebreth; Schmidt, Katharina; Cetinkaya, Raziye Boyar; Torp, Roald; Skogestad, Erik; Holm, Hans Kristian; Ahmad, Tahir Riaz; Hovde, Øistein; Ystrøm, Carl Magnus; Aballi, Batool; Sagosen, Arnt; Pedersen, Aina; Dahler, Stein; Pallenschat, Jens; Ricanek, Petr; Høivik, Marte Lie (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Background and aim: Modern treatment strategies for inflammatory bowel disease (IBD) are postulated to change the natural disease course. Inception cohort studies are the gold standard for investigating such changes. We ...
  • Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 
    Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...